Canada approves Pfizer’s Paxlovid drug

ealth Canada approved on Monday, January 17, Pfizer’s Paxlovid drug, which is a combination of two anti-virals intended for adults aged 18 and older with mild-to-moderate COVID-19 and who are at high risk of progressing to becoming seriously ill, including prospects of hospitalization or death. The treatment consists of two tablets of nirmatrelvir and one tablet of ritonavir taken together orally twice a day for five days. Paxlovid is the first approved at-home COVID-19 treatment in Canada. The drug is intended for use as soon as possible after diagnosis of COVID-19 and within five days of the start of symptoms.

Full Story